Participants, intervention and duration of treatment
| Study, year | Participants | Intervention | Duration of treatment |
| Budania et al,8 2013 | Patients with documented history of both type 2 diabetes and coronary artery disease. | Patients randomised to placebo or ranolazine 500 mg twice daily. | 8 weeks |
| Eckel et al,18 2015 | Patients with established type 2 diabetes, HbA1c 7%–10% and FPG 130–240 mg/dL, and treatment naïve or washed off all antidiabetic therapy. | Patients randomised to placebo or ranolazine 500 mg twice daily for 7 days followed by 1000 mg twice daily. | 24 weeks |
| Kipnes et al,19 2011 | Patients with type 2 diabetes, HbA1c 7%–11%, on non-insulin medical therapy. | Patient randomised to placebo or ranolazine 1000 mg twice daily. | 12 weeks |
| Kosiborod et al,9 2013 | Patients with type 2 diabetes, coronary artery disease and stable angina treated with 1–2 antianginals. | Patients were randomised to placebo or ranolazine 500 mg or 1000 mg twice daily. | 8 weeks |
| Morrow et al,14 2009 | Post hoc analysis of MERTIN-TIMI-36 trial, which recruited patients with non-ST elevation acute coronary syndrome. | Patients randomised to placebo or ranolazine as in intravenous infusion and followed by oral dose of 1000 mg twice daily. | 17 weeks |
| Pettus et al, 2015 – glimepiride add-on study | Patients with type 2 diabetes who have been on sulphonylureas. Glycaemic inclusion criteria included HbA1c 7%–9.5% and FPG 7.2–13.3 mmol/L (130–240 mg/dL). | Patients went through a stabilisation period of 2 weeks or 8 weeks on glimepiride (4 mg/day) and then randomised to placebo or ranolazine in addition to this background glimepiride therapy. Ranolazine started at 500 mg twice daily, and then up titrated to 1000 mg twice daily after 7 days. Patients were permitted to down titrate to 500 mg (or matched placebo) for intolerability. | 24 weeks |
| Pettus et al, 2015 – metformin add-on study | Patients with type 2 diabetes who have been on metformin. Glycaemic inclusion criteria included HbA1c 7%–9.5% and FPG 7.2–13.3 mmol/L (130–240 mg/dL). | Patients went through 8-week stabilisation period, during which metformin was titrated to 2000 mg/day. Patients randomised to ranolazine had their metformin dose reduced to 500 mg twice daily to avoid increased metformin exposure in ranolazine group as ranolazine 100 mg twice daily increases serum levels of metformin by 1.7-fold. | 24 weeks |
| Timmis et al, 2005 | Post hoc analysis of CARISA trial, which recruited patients with chronic angina and documented coronary artery disease. Study has explored post-treatment HbA1c change in patients with diabetes only. Study provided data for post-treatment FPG change in both diabetic and non-patients with diabetes. | Patients randomised to placebo, ranolazine 750 mg twice daily or ranolazine 1000 mg twice daily. | 12 weeks |
FPG, fasting plasma glucose.